About Genentech, Inc.
One of the world's leading biotechs, Genentech has a number of blockbuster cancer therapies based on its antibody (protein) technologies. It has approximately 40 medicines on the market with a pipeline of more than 20 new molecular entities in clinical development. Its portfolio contains well-known oncology drugs including Rituxan (non-Hodgkin's lymphoma), Avastin (colorectal and lung cancers), Herceptin (breast cancer), Tarceva (lung cancer), and Zelboraf (inoperable melanoma). Other drugs treat conditions such as age-related macular degeneration, cystic fibrosis, and asthma. Swiss pharmaceutical giant Roche owns the firm, which was founded in 1976. Genentech's San Francisco office serves as Roche's US headquarters.
Genentech has multiple products on the market for serious or life-threatening medical conditions. Its products include Actemra (Tocilizumab), for adults with moderately to severely active rheumatoid arthritis (RA); Activase (alteplase), a product indicated for treating patients with acute ischemic stroke (sudden stroke); and BONIVA, a prescription medicine used to treat osteoporosis in women after menopause. Genetech also supports people who needs help paying for its medicines, it has Genentech Access Solutions (insurance coverage) and Genentech Co-pay Services that helps people who have commercial insurance pay for Genentech medicine.
The company has headquarters in South San Francisco, California.
Sales and Marketing
The company serves scientist specialize on oncology, immunology, neuroscience, metabolism, infectious disease, ophthalmology, as well as patients and medical practitioners.
Genentech is dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Its transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.
Genentech continues to make strategic partnerships to develop and commercialize new drugs. In mid-2020, the company entered into a partnership with Regeneron in the fight against COVID-19 to develop, manufacture and distribute REGN-COV2, Regeneron's investigational antiviral antibody combination, to people around the globe. This collaboration is expected to increase the supply of REGN-COV2 to at least three and a half times the current capacity, with the potential for even further expansion.
The company also expanded its multiple sclerosis portfolio with investigational BTK inhibitor Fenebrutinib and initiated novel clinical trials for Ocrevus (ocrelizumab) in 2020. Genentech remains committed to advancing the science in MS by investigating potential new medicines such as fenebrutinib, with the ultimate goal of halting the progression of the disease.
Roche, which previously owned a majority stake in Genentech, made the company a wholly owned subsidiary in 2009 when it purchased the 44% of Genentech that it did not already own for about $47 billion.
Since taking full ownership of Genentech (previously a majority-owned subsidiary) in 2009, Roche has cut expenses by combining the two companies' global manufacturing and supply networks and by integrating the research, marketing, and administrative operations in the US, while at the same time working to maintain Genentech's innovative identity and culture.
1 Dna Way
South San Francisco, CA 94080-4990
Phone: (650) 225-1000
Employer Type: Privately Owned
CEO: Bill Anderson
Chairman: Severin Schwan
EVP Genentech Research and Early Development: Michael D. Varney
Employees (This Location): 2,000
Employees (All Locations): 11,174